These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30831102)

  • 1. Segesterone acetate/ethinyl estradiol 12-month contraceptive vaginal system safety evaluation.
    Gemzell-Danielsson K; Sitruk-Ware R; Creinin MD; Thomas M; Barnhart KT; Creasy G; Sussman H; Alami M; Burke AE; Weisberg E; Fraser I; Miranda MJ; Gilliam M; Liu J; Carr BR; Plagianos M; Roberts K; Blithe D
    Contraception; 2019 Jun; 99(6):323-328. PubMed ID: 30831102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bleeding profile associated with 1-year use of the segesterone acetate/ethinyl estradiol contraceptive vaginal system: pooled analysis from Phase 3 trials.
    Vieira CS; Fraser IS; Plagianos MG; Burke AE; Westhoff CL; Jensen J; Brache V; Bahamondes L; Merkatz R; Sitruk-Ware R; Blithe DL
    Contraception; 2019 Dec; 100(6):438-444. PubMed ID: 31398307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Segesterone acetate serum levels with a regression model of continuous use of the segesterone acetate/ethinyl estradiol contraceptive vaginal system.
    Liu JH; Plagianos M; Archer DF; Simon JA; Kaunitz AM; Graham S; Bernick B; Mirkin S
    Contraception; 2021 Sep; 104(3):229-234. PubMed ID: 33785318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-finding study of a 90-day contraceptive vaginal ring releasing estradiol and segesterone acetate.
    Chen MJ; Creinin MD; Turok DK; Archer DF; Barnhart KT; Westhoff CL; Thomas MA; Jensen JT; Variano B; Sitruk-Ware R; Shanker A; Long J; Blithe DL
    Contraception; 2020 Sep; 102(3):168-173. PubMed ID: 32416145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring.
    Weisberg E; Fraser IS; Lacarra M; Mishell DR; Alvarez F; Brache V; Nash HA
    Contraception; 1999 May; 59(5):311-8. PubMed ID: 10494485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials.
    Archer DF; Merkatz RB; Bahamondes L; Westhoff CL; Darney P; Apter D; Jensen JT; Brache V; Nelson AL; Banks E; Bártfai G; Portman DJ; Plagianos M; Dart C; Kumar N; Creasy GW; Sitruk-Ware R; Blithe DL
    Lancet Glob Health; 2019 Aug; 7(8):e1054-e1064. PubMed ID: 31231065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Satisfaction with a Segesterone Acetate and Ethinyl Estradiol Contraceptive Vaginal System Among Recent Oral Contraceptive or Hormonal Contraceptive Vaginal Ring Users.
    Jensen JT; Archer DF; Westhoff CL; Nelson AL; Graham S; Bernick B
    J Womens Health (Larchmt); 2023 Jul; 32(7):808-815. PubMed ID: 37253139
    [No Abstract]   [Full Text] [Related]  

  • 8. Comprehensive overview of the recently FDA-approved contraceptive vaginal ring releasing segesterone acetate and ethinylestradiol: A new year-long, patient controlled, reversible birth control method.
    Nelson AL
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):953-963. PubMed ID: 31526281
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of different insertion regimens on side effects with a combination contraceptive vaginal ring.
    Weisberg E; Fraser IS; Lacarra M; Mishell DR; Jackanicz T
    Contraception; 1997 Oct; 56(4):233-9. PubMed ID: 9408704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol.
    Weisberg E; Fraser IS; Mishell DR; Lacarra M; Darney P; Jackanicz TM
    Contraception; 1999 May; 59(5):305-10. PubMed ID: 10494484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of concurrent vaginal miconazole treatment on the absorption and exposure of Nestorone® (segesterone acetate) and ethinyl estradiol delivered from a contraceptive vaginal ring: a randomized, crossover drug-drug interaction study.
    Simmons KB; Kumar N; Plagianos M; Roberts K; Hoskin E; Han L; Alami M; Creasy G; Variano B; Merkatz R
    Contraception; 2018 Mar; 97(3):270-276. PubMed ID: 29097225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A technology evaluation of Annovera: a segesterone acetate and ethinyl estradiol vaginal ring used to prevent pregnancy for up to one year.
    Micks EA; Jensen JT
    Expert Opin Drug Deliv; 2020 Jun; 17(6):743-752. PubMed ID: 32410464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for and outcomes of ring expulsions with a 1-year contraceptive vaginal system.
    Plagianos MG; Ramanadhan S; Merkatz RB; Brache V; Friedland BA; Haddad LB
    Am J Obstet Gynecol; 2024 May; 230(5):548.e1-548.e8. PubMed ID: 38295968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contraceptive vaginal ring containing segesterone acetate and ethinyl estradiol: long-acting, patient-controlled, procedure-free, reversible prescription birth control.
    Paton DM
    Drugs Today (Barc); 2019 Jul; 55(7):449-457. PubMed ID: 31347613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A New Year-Long Combination Hormonal Contraceptive.
    Blakely KK
    Nurs Womens Health; 2019 Apr; 23(2):172-176. PubMed ID: 30836070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety, and tolerability of a levonorgestrel/ethinyl estradiol transdermal delivery system: Phase 3 clinical trial results.
    Nelson AL; Kaunitz AM; Kroll R; Simon JA; Poindexter AN; Castaño PM; Ackerman RT; Flood L; Chiodo JA; Garner EI;
    Contraception; 2021 Mar; 103(3):137-143. PubMed ID: 33259782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Annovera - a new contraceptive vaginal ring.
    Med Lett Drugs Ther; 2019 Dec; 61(1587):197-198. PubMed ID: 31999667
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol.
    Akerlund M; Røde A; Westergaard J
    Br J Obstet Gynaecol; 1993 Sep; 100(9):832-8. PubMed ID: 8218004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age.
    Kirkman RJ; Pedersen JH; Fioretti P; Roberts HE
    Contraception; 1994 Jan; 49(1):33-46. PubMed ID: 8137624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Segesterone Acetate and Ethinyl Estradiol Vaginal Ring (Annovera) for Contraception.
    Lee AL
    Am Fam Physician; 2020 May; 101(10):618-620. PubMed ID: 32412221
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.